| 肝动脉化疗栓塞联合射频消融对肝癌患者细胞免疫功能的影响 |
| |
| 引用本文： | 黄彦华,徐锋,钟丽云.肝动脉化疗栓塞联合射频消融对肝癌患者细胞免疫功能的影响[J].中华全科医学,2019,17(9):1521. |
| |
| 作者姓名： | 黄彦华 徐锋 钟丽云 |
| |
| 作者单位： | 1. 嘉兴市第二医院肝胆外科, 浙江 嘉兴 314000; |
| |
| 基金项目： | 浙江省医药卫生科技计划项目(2016RCA012) |
| |
| 摘 要： | 目的 观察单独肝动脉化疗栓塞(TACE)治疗及联合射频消融(RFA)治疗对肝癌患者治疗后血清T淋巴细胞亚群及转化生长因子β1(TGF-β1)水平变化的影响，为进一步提高肝癌患者治疗效果提供参考。 方法 以2016年1月—2018年6月嘉兴市第二医院收治的72肝例癌患者为研究对象，采用随机数字表法分为2组，对照组为TACE组，观察组为TACE联合RFA组，分别检测2组治疗前后同时相外周血中T淋巴细胞亚群(CD4+、CD8+、CD4+/CD8+)及TGF-β1的变化情况，数据采用SPSS 23.0统计学软件进行分析。 结果 治疗前，对照组和观察组患者血清CD4+、CD8+及CD4+/CD8+差异均无统计学意义(均P＞0.05)，治疗后第2周和第4周，观察组患者血清CD4+及CD4+/CD8+均高于对照组(均P＜0.05)，而CD8+低于对照组(均P＜0.05)。治疗前，对照组和观察组患者血清TGF-β1水平差异无统计学意义(P＞0.05)，治疗后第2周和第4周，观察组患者血清TGF-β1水平均低于对照组(均P＜0.05)。对照组的治疗总有效率为72.22%，而观察组的治疗总有效率为91.67%，观察组高于对照组(P＜0.05)。 结论 TACE治疗对肝癌患者的细胞免疫造成一过性抑制，随着时间的延长，患者的细胞免疫功能有一定程度恢复，而TACE联合RFA治疗则能增强细胞免疫功能。
|
| 关 键 词： | 肝癌 肝动脉化疗栓塞 射频消融 细胞免疫 |
| 收稿时间： | 2019-01-28 |
Effects of transcatheter arterial chemoembolization combined with radiofrequency ablation on cellular immune function in patients with hepatocellular carcinoma |
| |
| Affiliation: | Department of Hepatobiliary Surgery, the Second Hospital of Jiaxing City, Jiaxing, Zhejiang 314000, China |
| |
| Abstract: | Objective To observe the effects of transcatheter arterial chemoembolization (TACE) alone and radiofrequency ablation (RFA) on serum T lymphocyte subsets and transforming growth factor-β1 (TGF-β1) levels in patients with hepatocellular carcinoma (HCC) after treatment, so as to provide reference for further improving the therapeutic effect of HCC patients. Methods Seventy-two patients with HCC admitted to our hospital from January 2016 to June 2018 were randomly divided into two groups. The control group was TACE group and the observation group was TACE combined with RFA group. The changes of T lymphocyte subsets (CD4+, CD8+, CD4+/CD8+) and TGF-β1 in peripheral blood of the two groups before and after treatment were detected respectively. The data were analyzed by SPSS 23.0 statistical software. Results There was no significant difference in serum CD4+, CD8+, CD4+/CD8+ between the control group and the observation group before treatment (all P>0.05). At the 2nd and 4th weeks after treatment, the serum CD4+ and CD4+/CD8+ of the observation group were higher than those of the control group (all P<0.05), while CD8+ was lower than that of the control group (all P<0.05). Before treatment, there was no significant difference in the level of serum TGF-β1 between the control group and the observation group (P>0.05). At the 2nd and 4th weeks after treatment, the level of serum TGF-β1 in the observation group was lower than that in the control group (all P<0.05). The total effective rate of the control group was 72.22%, while that of the observation group was 91.67%. The total effective rate of the observation group was higher than that of the control group (P<0.05). Conclusion TACE treatment can temporarily inhibit the cellular immunity of patients with hepatocellular carcinoma. With the prolongation of time, the cellular immune function of patients recovers to a certain extent, while TACE combined with RFA treatment can enhance the cellular immune function. |
| |
| Keywords: | |
|
| 点击此处可从《中华全科医学》浏览原始摘要信息 |
|
点击此处可从《中华全科医学》下载全文 |
|
